Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n-of-1 trial of weekly-interval red cell transfusion in myelodysplastic syndromes.
RBC transfusion
transfusion practices (adult)
transfusion practices (oncology-hematology)
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
12 Jan 2024
12 Jan 2024
Historique:
revised:
30
11
2023
received:
29
07
2023
accepted:
07
12
2023
medline:
12
1
2024
pubmed:
12
1
2024
entrez:
12
1
2024
Statut:
aheadofprint
Résumé
Anemia in myelodysplastic syndromes (MDS) is associated with poorer health-related quality of life (HRQoL) and physical function, and is frequently treated with transfusions. The current common practice of transfusing multiple red blood cells (RBC) units every 2-4 weeks may result in peaks/troughs in hemoglobin (Hb) level, yet maintaining a stable Hb may better improve HRQoL. We describe a study protocol aiming to investigate the feasibility of weekly low-dose RBC transfusion in MDS patients, including assessing HRQoL and physical function outcomes. In this n-of-1 pilot study, patients receive two treatment arms, with randomly allocated treatment sequence: arm A (patient's usual transfusion schedule) and arm B (weekly transfusion, individualized per patient). To facilitate timely delivery of weekly transfusion, extended-matched RBCs are provided, with transfusion based upon the previous week's Hb/pre-transfusion testing results to eliminate delays of awaiting contemporaneous cross-matching. Primary outcome is the feasibility of delivering weekly transfusion. Secondary outcomes include HRQoL, functional activity measurements, RBC usage, and alloimmunization rates. A qualitative substudy explores patient and staff experiences. The trial is open in Australia, Netherlands, and UK. The first patient was recruited in 2020. Inter-country differences in providing RBCs are observed, including patient genotyping versus serological phenotyping to select compatible units. This pilot trial evaluates a novel personalized transfusion approach of weekly matched RBC transfusion and challenges the dogma of current routine pre-transfusion matching practice. Findings on study feasibility, HRQoL, and physical functional outcomes and the qualitative substudy will inform the design of a larger definitive trial powered for clinical outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Anemia in myelodysplastic syndromes (MDS) is associated with poorer health-related quality of life (HRQoL) and physical function, and is frequently treated with transfusions. The current common practice of transfusing multiple red blood cells (RBC) units every 2-4 weeks may result in peaks/troughs in hemoglobin (Hb) level, yet maintaining a stable Hb may better improve HRQoL. We describe a study protocol aiming to investigate the feasibility of weekly low-dose RBC transfusion in MDS patients, including assessing HRQoL and physical function outcomes.
STUDY DESIGN AND METHODS
METHODS
In this n-of-1 pilot study, patients receive two treatment arms, with randomly allocated treatment sequence: arm A (patient's usual transfusion schedule) and arm B (weekly transfusion, individualized per patient). To facilitate timely delivery of weekly transfusion, extended-matched RBCs are provided, with transfusion based upon the previous week's Hb/pre-transfusion testing results to eliminate delays of awaiting contemporaneous cross-matching. Primary outcome is the feasibility of delivering weekly transfusion. Secondary outcomes include HRQoL, functional activity measurements, RBC usage, and alloimmunization rates. A qualitative substudy explores patient and staff experiences.
RESULTS
RESULTS
The trial is open in Australia, Netherlands, and UK. The first patient was recruited in 2020. Inter-country differences in providing RBCs are observed, including patient genotyping versus serological phenotyping to select compatible units.
DISCUSSION
CONCLUSIONS
This pilot trial evaluates a novel personalized transfusion approach of weekly matched RBC transfusion and challenges the dogma of current routine pre-transfusion matching practice. Findings on study feasibility, HRQoL, and physical functional outcomes and the qualitative substudy will inform the design of a larger definitive trial powered for clinical outcomes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Newcastle Hospitals Charitable Funds
Organisme : Charity at Leeds
Organisme : National Health and Medical Research Council
Organisme : National Blood Authority
Organisme : Monash Haematology
Organisme : Australian and New Zealand Society of Blood Transfusion
Informations de copyright
© 2024 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.
Références
McQuilten ZK, Polizzotto MN, Wood EM, Sundararajan V. Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: an Australian population-based study 1998 to 2008. Transfusion. 2013;53:1714-1721.
Killick SB, Carter C, Culligan D, Dalley C, das-Gupta E, Drummond M, et al. Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol. 2014;164:503-525.
Vijenthira A, Starkman R, Lin Y, Stanworth SJ, Bowen D, Harrison L, et al. Multi-national survey of transfusion experiences and preferences of patients with myelodysplastic syndrome. Transfusion. 2022;62:1355-1364.
National Blood Authority. Module 3 Medical. Canberra, Australia: National Blood Authority; 2012.
Pinchon DJ, Stanworth SJ, Doree C, Brunskill S, Norfolk DR. Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review. Am J Hematol. 2009;84:671-677.
Mo A, McQuilten ZK, Wood EM, Weinkove R. Red cell transfusion thresholds in myelodysplastic syndromes: a clinician survey to inform future clinical trials. Intern Med J. 2017;47:695-698.
Bruhn R, Karafin MS, Hilton JF, Hilton JF, Kaidarova Z, Spencer BR, et al. Early and sustained improvement in fatigue-related quality of life following red blood cell transfusion in outpatients. Qual Life Res. 2020;29:2737-2744.
St. Lezin E, Karafin MS, Bruhn R, Chowdhury D, Qu L, Bialkowski W, et al. Therapeutic impact of red blood cell transfusion on anemic outpatients: the RETRO study. Transfusion. 2019;59:1934-1943.
Mo A, Poynton M, Wood E, Shortt J, Brunskill SJ, Doree C, et al. Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review. Blood Rev. 2023;61:101114.
Stanworth SJ, Killick S, McQuilten ZK, Karakantza M, Weinkove R, Smethurst H, et al. Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. Br J Haematol. 2020;189:279-290.
Caocci G, Baccoli R, Ledda A, Littera R, La Nasa G. A mathematical model for the evaluation of amplitude of hemoglobin fluctuations in elderly anemic patients affected by myelodysplastic syndromes: correlation with quality of life and fatigue. Leuk Res. 2007;31:249-252.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of Tumours of Haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2017.
Kravitz RL, Duan N, Esclick NG, Kaplan HC, Larson E. Design and implementation of N-of-1 trials: a user's guide. Maryland: AHRQ Publication, US Department of Health and Human Services; 2014.
Australian and New Zealand Society of Blood Transfusion. Guidelines for transfusion and immunohaematology laboroatory practice. 1st ed. Australia: ANZSBT; 2016.
Milkins C, Berryman J, Cantwell C, Elliott C, Haggas R, Jones J, et al. Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. Transfus Med. 2013;23:3-35.
Evers D, Middelburg RA, de Haas M, Zalpuri S, de Vooght KMK, van de Kerkhof D, et al. Red-blood-cell alloimmunisation in relation to antigens' exposure and their immunogenicity: a cohort study. Lancet Haematol. 2016;3:e284-e292.
Sanz C, Nomdedeu M, Belkaid M, Martinez I, Nomdedeu B, Pereira A. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Transfusion. 2013;53:710-715.
Singhal D, Kutyna MM, Chhetri R, Wee LYA, Hague S, Nath L, et al. Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome. Haematologica. 2017;102:2021-2029.
Schonewille H, Honohan A, van der Watering LM, Hudig F, Te Boekhorst PA, Koopman-van Gemert AW, et al. Incidence of alloantibody formation after ABO-D or extended matched red blood cell transfusions: a randomized trial (MATCH study). Transfusion. 2016;56:311-320.
Reid M, Lomas-Francis C, Olsson M. The blood group antigen FactsBook. 3rd ed. United Kingdom: Elsevier; 2012.
Molnar R, Johnson R, Sweat LT, Geiger TL. Absence of D alloimmunization in D- pediatric oncology patients receiving D-incompatible single-donor platelets. Transfusion. 2002;42:177-182.
Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727-1736.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
Abel GA, Efficace F, Buckstein RJ, Tinsley S, Jurcic JG, Martins Y, et al. Prospective international validation of the quality of life in myelodysplasia scale (QUALMS). Haematologica. 2016;101:781-788.
Callaway L, Winkler D, Tippett A, Migliorini C, Herd N, Willer B. The community integration questionnaire-revised (CIQ-R). Melbourne, Australia: Summer Foundation Ltd; 2014.
American thoracic society statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111-117.
Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011;40:423-429.
Innerd P, Catt M, Collerton J, Davies K, Trenell M, Kirkwood TBL, et al. A comparison of subjective and objective measures of physical activity from the Newcastle 85+ study. Age Ageing. 2015;44:691-694.
Ramires VV, Wehrmeister FC, Bohm AW, Galliano L, Ekelund U, Brage S, et al. Physical activity levels objectively measured among older adults: a population-based study in a southern city of Brazil. Int J Behav Nutr Phys Act. 2017;14:13.
Sabia S, Cogranne P, van Hees VT, Bell JA, Elbaz A, Kivimaki M, et al. Physical activity and adiposity markers at older ages: accelerometer vs questionnaire data. J Am Med Dir Assoc. 2015;16(438):e7-e13.
Charman SJ, van Hees VT, Quinn L, Dunford JR, Bawamia B, Veerasamy M, et al. The effect of percutaneous coronary intervention on habitual physical activity in older patients. BMC Cardiovasc Disord. 2016;16:248.
Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18:59-82.
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77-101.
Jansen AJ, Essink-Bot ML, Beckers EA, Hop WC, Schipperus MR, van Rhenen DJ. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol. 2003;121:270-274.
Buckstein RJ, Prica A, Leber B, Heddle N, Yee KWL, Stanworth SJ, et al. RBC-enhance: a randomized pilot feasibility trial of red cell transfusion thresholds in myelodysplastic syndromes. Blood. 2020;136:3-4.
Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28:2847-2852.
Shih AW, Liu A, Elsharawi R, Crowther MA, Cook RJ, Heddle NM. Systematic reviews of guidelines and studies for single versus multiple unit transfusion strategies. Transfusion. 2018;58:2841-2860.
Tormey CA, Hendrickson JE. Transfusion-related red blood cell alloantibodies: induction and consequences. Blood. 2019;133:1821-1830.
Klein HG, Flegel WA, Natanson C. Red blood cell transfusion: precision vs imprecision medicine. JAMA. 2015;314:1557-1558.
Mo A, Stanworth SJ, Shortt J, Wood EM, McQuilten ZK. Red cell transfusions: is less always best? Transfusion. 2021;61:2195-2203.
Jansen AG, van den Bosch J, Te Boekhorst PA, Schipperus MR, Beckers EA. Results of the prematurely terminated TEMPLE randomized controlled trial in patients with myelodysplastic syndrome: liberal versus restrictive red blood cell transfusion threshold. Transfusion. 2020;60:879-881.